Abbott and Sanofi Partner to Integrate Glucose Sensing and Insulin Delivery

Abbott and Sanofi are partnering up to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition.

The two companies plan to develop tools that combine the revolutionary FreeStyle Libre technology with Sanofi′s insulin dosing information for future smartpens, insulin titration apps, and cloud software.

The non-exclusive collaboration will initially enable data sharing, at the consent of the user, between Abbott′s FreeStyle Libre mobile app and cloud software and Sanofi′s connected insulin pens, apps and cloud software that are currently in development.

This data sharing will enable both people with diabetes and their doctors to make better-informed treatment decisions around medication, nutrition, and lifestyle.

“As the global leader in continuous glucose monitoring, we see a significant opportunity to impact the health of millions of people living with diabetes by developing new tools and connectivity with Sanofi, a leader in the insulin space,” said Jared Watkin, senior vice president, Diabetes Care, Abbott in a statement.

“Building a digital ecosystem around FreeStyle Libre simplifies the user experience by consolidating how people get their data – both through offering Abbott′s digital health tools and by working with other diabetes and technology leaders,” Watkins added.

Sanofi is currently working to provide connected pens, apps and cloud software that will be compatible with the FreeStyle Libre system and its compatible digital health tools.

The two companies aim to bring this to people with diabetes within the next few years, pending local regulatory approvals.

“This strategic relationship with Abbott is representative of the next evolution of our commitment for better diabetes care by incorporating digital tools into the daily life of people living with diabetes,” said Gustavo Pesquin, senior vice president of Global Diabetes and Cardiovascular Franchise at Sanofi.

“By partnering with Abbott, we are a step closer to realizing our connected ecosystem, which would help improve control and the quality of life decision cycle for patients through individualized glycemic management of diabetes,” he added.

About the FreeStyle Libre System

Abbott’s FreeStyle Libre is a sensor-based glucose monitoring system that is used worldwide.

It reads glucose levels through a sensor that can be worn on the back of the upper arm eliminating the need for finger sticks.

FreeStyle Libre has secured partial or full reimbursement in 33 countries, including Canada, France, Ireland, Japan, the United Kingdom, and the U.S. For more information, visit: https://www.freestylelibre.us.

Source: